In contrast, tubulin is present only in the central region of the growth cone, where it forms an extensive network of microtubules. SOD1G93Amice. Histologic evaluation at 90 and 125 days revealed that anti-NRP1Aantibody reduced neuromuscular junction denervation and attenuated pathologic alterations in ventral roots at late-stage disease. These data suggest that peripheral NRP1Asignaling is usually involved in the pathobiology of this ALS model and that antagonizing Sema3A/NRP1 binding or downstream signals could have implications for the treatment of ALS. Key Words:Amyotrophic lateral sclerosis, CRMP2, Neuromuscular junction, Neuropilin-1, NSC-34 motor neuronlike cells, Semaphorin 3A == INTRODUCTION == Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease that is, in part, a progressive distal axonopathy (14). In SOD1G93Atransgenic mice, which model human familial ALS (fALS), one of the earliest neuronal disease alterations is usually neuromuscular junction (NMJ) disintegration, which is followed by axon degeneration that progresses to spinal motor neuron death (1,4). In fALS mouse models and human sporadic ALS, changes suggesting a period of distal axon remodeling and muscle mass reinnervation occur before the death of motor neurons at end-stage disease (1). Triggers for axon retraction from motor end plates and subsequent drivers of axonal deterioration remain unknown. Because motor neuron disease in fALS mouse models linked to mutant superoxide dismutase 1 (SOD1) is usually noncell-autonomous and depends on transgene expression in non-neuronal cells, glial factors may contribute to either the initiation or the progression of motor neuron degeneration (2,5). There is reason to suspect that Mycophenolate mofetil (CellCept) aberrant expression of axon repulsion factors near the NMJ or activation of their downstream pathways may contribute to the distal axonopathy of ALS. Semaphorin 3A (Sema3A), an important axon guidance cue involved in developmental neural patterning, is usually upregulated in specific populations of terminal Schwann cells near fast-fatigable Type IIb/x muscle mass fibers that are particularly vulnerable to denervation in ALS (6). Semaphorin 3A signaling through its receptor neuropilin-1 (NRP1) and plexin A coreceptors triggers axonal retraction by destabilizing microtubules and microfilament networks via a mechanism involving the collapsin response mediator protein (CRMP) class of microtubule-associated proteins (711) (Fig. 1). Collapsin response mediator proteins have been independently implicated in ALS because 1) the cytoskeleton-stabilizing CRMP2 is usually antagonized by isoforms of CRMP4 that become induced in ALS motor neurons, probably in response to neuroinflammatory factors (12), and 2) treatment of SOD1G93Amice with the CRMP2-binding experimental therapeutic lanthionine ketimine ethyl ester slows disease Serpinf1 progression (13). == FIGURE 1. == Schematic diagram of Sema3A signaling through CRMP2 and CRMP4 via the NRP1/plexin A receptor system and mechanism of anti-NRP1Aantibody action. Neuropilin-1 can bind either Sema3A or VEGF at impartial docking domains. Heterodimerization with plexin coreceptors triggers activation of small GTPases, leading to downstream events, particularly phosphorylation of the microtubule-associated protein CRMP2. Recent findings also implicate the CRMP4 isoform in some aspects of Sema3A signaling (11). Mycophenolate mofetil (CellCept) CRMP2 phosphorylation leads to microtubule instability and indirectly to actin cytoskeletal rearrangements. In developing axons, such activation of the Sema3A/NRP1/CRMP2 axis promotes growth cone collapse and axon retraction away from improper target cells. In the adult animal, Sema3A released from terminal Schwann cells could inhibit compensatory axon sprouting and help coordinate NMJ remodeling after injury. In the context of ALS, improper or prolonged overstimulation of the system could contribute to distal axonopathy. We Mycophenolate mofetil (CellCept) hypothesize that the ability of anti-NRP1Aantibody to selectively bind to the CUB domains (a1 and a2) of NRP1 and to block Sema3A-induced neuron collapse without interfering with the binding of VEGF to the b1 and b2 domains of NRP1 may prevent axon retraction and safeguard the integrity of NMJs. Cdk5, cyclin-dependent kinase 5; Fer, tyrosine protein kinase Fer; GSK3, glycogen synthase kinase 3. This study directly assessments the hypothesis that ALS motor neuron retraction from vulnerable motor end plates occurs in response to.